Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

NCT05676749 is registered in ClinicalTrials.gov with AbelZeta Inc. as lead sponsor.

NCT NCT05676749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer
Lead sponsor
AbelZeta Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 29, 2024
Completion date
December 30, 2025
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer